ES2808906T3 - Sistema de expresión bacteriano cistrónico doble - Google Patents
Sistema de expresión bacteriano cistrónico doble Download PDFInfo
- Publication number
- ES2808906T3 ES2808906T3 ES15745247T ES15745247T ES2808906T3 ES 2808906 T3 ES2808906 T3 ES 2808906T3 ES 15745247 T ES15745247 T ES 15745247T ES 15745247 T ES15745247 T ES 15745247T ES 2808906 T3 ES2808906 T3 ES 2808906T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- expression
- fragment
- inclusion bodies
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 91
- 239000013598 vector Substances 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims abstract description 34
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 30
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 25
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 25
- 239000002157 polynucleotide Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 19
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 19
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 230000007928 solubilization Effects 0.000 claims abstract description 4
- 238000005063 solubilization Methods 0.000 claims abstract description 4
- 230000001131 transforming effect Effects 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 229960003876 ranibizumab Drugs 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 210000001322 periplasm Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 4
- 108010019598 Liraglutide Proteins 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960002701 liraglutide Drugs 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 101150040383 pel2 gene Proteins 0.000 description 3
- 101150050446 pelB gene Proteins 0.000 description 3
- 101150009573 phoA gene Proteins 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 101150076271 SAK gene Proteins 0.000 description 2
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 2
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 2
- 101710145796 Staphylokinase Proteins 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- -1 Exanetide Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108700003859 araC Genes Proteins 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108010073046 teduglutide Proteins 0.000 description 1
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 1
- 229960002444 teduglutide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/34—Cucurbitaceae, e.g. bitter melon, cucumber or watermelon
- A01H6/342—Citrullus lanatus [watermelon]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/27—Erwinia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24029—Aureolysin (3.4.24.29)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Physiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2245MU2014 | 2014-07-09 | ||
| PCT/IB2015/055189 WO2016005931A1 (en) | 2014-07-09 | 2015-07-09 | Dual cistronic bacterial expression system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2808906T3 true ES2808906T3 (es) | 2021-03-02 |
Family
ID=53773474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15745247T Active ES2808906T3 (es) | 2014-07-09 | 2015-07-09 | Sistema de expresión bacteriano cistrónico doble |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10329571B2 (enExample) |
| EP (1) | EP3167065B1 (enExample) |
| JP (1) | JP6748061B2 (enExample) |
| CN (1) | CN106661588B (enExample) |
| AU (1) | AU2015287296A1 (enExample) |
| BR (1) | BR112017000389A2 (enExample) |
| CA (1) | CA2954594A1 (enExample) |
| CY (1) | CY1123303T1 (enExample) |
| DK (1) | DK3167065T3 (enExample) |
| ES (1) | ES2808906T3 (enExample) |
| HR (1) | HRP20200996T1 (enExample) |
| HU (1) | HUE050300T2 (enExample) |
| LT (1) | LT3167065T (enExample) |
| MX (1) | MX378585B (enExample) |
| PH (1) | PH12017500047A1 (enExample) |
| PL (1) | PL3167065T3 (enExample) |
| PT (1) | PT3167065T (enExample) |
| RU (1) | RU2732148C2 (enExample) |
| SI (1) | SI3167065T1 (enExample) |
| WO (1) | WO2016005931A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6435770B2 (ja) * | 2014-01-21 | 2018-12-12 | 東ソー株式会社 | シグナルペプチドをコードするポリヌクレオチドおよびそれを用いたタンパク質の製造方法 |
| WO2017021819A1 (en) * | 2015-07-31 | 2017-02-09 | Dr. Reddy’S Laboratories Limited | Process for preparation of protein or peptide |
| KR102607655B1 (ko) | 2017-05-19 | 2023-11-28 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 리폴딩된 재조합 인간화 라니비주맙의 제조 방법 |
| ES2965485T3 (es) * | 2017-08-23 | 2024-04-15 | Novartis Ag | Sistema de expresión de proteínas con múltiples copias génicas |
| CN113631567B (zh) * | 2018-07-06 | 2025-02-07 | 瓦克化学股份公司 | 在发酵方法中释放重组蛋白的细菌菌株 |
| JP7762935B2 (ja) * | 2019-01-31 | 2025-10-31 | Ｓｐｉｂｅｒ株式会社 | 組換え細胞、発現構築物、及び組換えタンパク質の製造方法 |
| KR20210148288A (ko) * | 2019-04-02 | 2021-12-07 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 생체내 리폴딩된 항체 단편의 클로닝 및 발현 |
| CN114774453B (zh) * | 2022-03-14 | 2023-04-21 | 湖北大学 | 一种运动发酵单胞菌基因表达严谨调控系统的构建方法和应用 |
| CN116334118A (zh) * | 2023-02-23 | 2023-06-27 | 四川大学 | 一种原核体系中单启动子控制多个颗粒蛋白亚基组装同源等同体在胞内恒定比例表达并共自组装的方法 |
| CN118995554B (zh) * | 2024-09-09 | 2025-07-04 | 江南大学 | 一种大肠杆菌整合表达体系及其在酶高效表达中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| JP4309656B2 (ja) | 2000-12-14 | 2009-08-05 | ジェネンテック・インコーポレーテッド | 原核生物で生成させた抗体とその用途 |
| CA2454731C (en) | 2001-08-27 | 2010-11-02 | Genentech, Inc. | A system for antibody expression and assembly |
| DK2046382T3 (en) * | 2006-07-10 | 2016-12-12 | Esbatech Alcon Biomed Res Unit | scFv Antibodies which passes through the epithelial and / or endothelial layer |
| RU2413769C1 (ru) * | 2009-12-24 | 2011-03-10 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-32a, КОДИРУЮЩАЯ ГЕН ЛИГАНД-СВЯЗЫВАЮЩЕГО ДОМЕНА РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА-β ЧЕЛОВЕКА (TβRII), ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ СЛИТНОГО БЕЛКА ТИОРЕДОКСИН/TβRII И СПОСОБ РЕНАТУРАЦИИ И ОЧИСТКИ ЦЕЛЕВОГО БЕЛКА TβRII |
| GB201002730D0 (en) * | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
| US8853380B2 (en) | 2010-06-04 | 2014-10-07 | Lupin Limited | Modified SAK gene for the production of recombinant proteins |
| CA2904146C (en) * | 2013-03-08 | 2023-03-21 | Neuclone Biologics Pty Ltd | A cell expression system |
| CA2911087A1 (en) * | 2013-04-30 | 2014-11-06 | Harish Shandilya | Novel cloning, expression & purification method for the preparation of ranibizumab |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
-
2015
- 2015-07-09 ES ES15745247T patent/ES2808906T3/es active Active
- 2015-07-09 RU RU2017102578A patent/RU2732148C2/ru active
- 2015-07-09 LT LTEP15745247.5T patent/LT3167065T/lt unknown
- 2015-07-09 WO PCT/IB2015/055189 patent/WO2016005931A1/en not_active Ceased
- 2015-07-09 DK DK15745247.5T patent/DK3167065T3/da active
- 2015-07-09 PT PT157452475T patent/PT3167065T/pt unknown
- 2015-07-09 CA CA2954594A patent/CA2954594A1/en not_active Abandoned
- 2015-07-09 MX MX2017000332A patent/MX378585B/es unknown
- 2015-07-09 PL PL15745247T patent/PL3167065T3/pl unknown
- 2015-07-09 US US15/324,105 patent/US10329571B2/en not_active Expired - Fee Related
- 2015-07-09 HR HRP20200996TT patent/HRP20200996T1/hr unknown
- 2015-07-09 HU HUE15745247A patent/HUE050300T2/hu unknown
- 2015-07-09 JP JP2017500849A patent/JP6748061B2/ja active Active
- 2015-07-09 EP EP15745247.5A patent/EP3167065B1/en active Active
- 2015-07-09 BR BR112017000389A patent/BR112017000389A2/pt not_active Application Discontinuation
- 2015-07-09 SI SI201531263T patent/SI3167065T1/sl unknown
- 2015-07-09 AU AU2015287296A patent/AU2015287296A1/en not_active Abandoned
- 2015-07-09 CN CN201580037078.3A patent/CN106661588B/zh not_active Expired - Fee Related
-
2017
- 2017-01-06 PH PH12017500047A patent/PH12017500047A1/en unknown
-
2019
- 2019-04-24 US US16/393,338 patent/US11365418B2/en active Active
-
2020
- 2020-06-25 CY CY20201100580T patent/CY1123303T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1123303T1 (el) | 2021-12-31 |
| EP3167065B1 (en) | 2020-03-25 |
| US20190309313A1 (en) | 2019-10-10 |
| CN106661588B (zh) | 2020-11-06 |
| CA2954594A1 (en) | 2016-01-14 |
| AU2015287296A1 (en) | 2017-02-02 |
| WO2016005931A1 (en) | 2016-01-14 |
| HRP20200996T1 (hr) | 2021-01-08 |
| US11365418B2 (en) | 2022-06-21 |
| US20170159060A1 (en) | 2017-06-08 |
| BR112017000389A2 (pt) | 2018-01-23 |
| US10329571B2 (en) | 2019-06-25 |
| DK3167065T3 (da) | 2020-07-06 |
| PL3167065T3 (pl) | 2020-11-16 |
| CN106661588A (zh) | 2017-05-10 |
| EP3167065A1 (en) | 2017-05-17 |
| SI3167065T1 (sl) | 2020-09-30 |
| HUE050300T2 (hu) | 2020-11-30 |
| JP2017520261A (ja) | 2017-07-27 |
| PT3167065T (pt) | 2020-07-01 |
| LT3167065T (lt) | 2020-07-27 |
| RU2732148C2 (ru) | 2020-09-11 |
| MX2017000332A (es) | 2017-07-28 |
| MX378585B (es) | 2025-03-10 |
| PH12017500047A1 (en) | 2017-05-22 |
| JP6748061B2 (ja) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2808906T3 (es) | Sistema de expresión bacteriano cistrónico doble | |
| ES2732907T3 (es) | Procedimiento de expresión | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| US9914770B2 (en) | Cloning, expression and purification method for the preparation of ranibizumab | |
| JP2015531751A (ja) | 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物 | |
| US20070274985A1 (en) | Antibody | |
| US10113193B2 (en) | Method for optimizing the assembly and production of hetero-multimeric protein complexes | |
| WO2015015518A2 (en) | Process for production of insulin and insulin analogues | |
| ES2331573T3 (es) | Vector de expresion para la secrecion de un fragmento de anticuerpo usando una secuencia señal de e. coli y procedimiento para la produccion en serie del fragmento de anticuerpo. | |
| Pasupuleti et al. | Genetic code expansion in E. coli enables production of a functional ‘ready-to-click’T cell receptor-specific scFv | |
| Zhang et al. | Production of soluble and functional engineered antibodies in Escherichia coli improved by FkpA | |
| Ye et al. | High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli | |
| ES2792350T3 (es) | Secuencia señal secretora de organismos eucariotas para la expresión recombinante en organismos procariotas | |
| KR102603693B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 폴돈 도메인이 연결된 융합 단백질 및 이의 용도 | |
| HK1246822A1 (zh) | 双顺反子细菌表达系统 | |
| RU2115729C1 (ru) | Рекомбинантная плазмидная днк, кодирующая препроинсулин человека | |
| US10465220B2 (en) | Expression process | |
| HK1246822B (zh) | 双顺反子细菌表达系统 | |
| CN106661117A (zh) | IgG杂合型抗TNFα和IL‑17A双特异性抗体 | |
| US20250312452A1 (en) | Antibody targeting claudin18.2 and its applications | |
| CN105198999A (zh) | 一种融合蛋白、其制备方法及其应用 | |
| KR20250115936A (ko) | 수용체 이량체화를 유도하는 작용제 항체를 스크리닝 하는 방법 | |
| CA3108573A1 (en) | Recombinant plant-derived antibodies and fc variants and related methods |